# Junta clínica — PT-pseudo_11fe9c6ca833 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_11fe9c6ca833",
  "pid": "PT-pseudo_11fe9c6ca833",
  "task": 1,
  "psa": 190.0,
  "age": 66,
  "months": 2,
  "pirads": "5",
  "psad": 4.097,
  "psav": 41.57,
  "psap": 125.1,
  "vol": 46.38,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.9718793,
  "medhx": "Hypertension, Coronary artery disease",
  "meds": "valsartan, lisinopril, metoprolol, aspirin 80 mg",
  "notes": "PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.",
  "pmhx": [
    "Hypertension",
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "61 kg",
    "height": "167 cm",
    "bmi": "21.9",
    "bp": "125/89 mmHg",
    "hr": "77 bpm",
    "smoking": "Ex-smoker (10 pack-yr, quit 2022)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "02 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer."
    },
    {
      "s": "History",
      "t": "A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses."
    }
  ],
  "occupation": "civil engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "4 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_11fe9c6ca833
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 190.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 4.097 ng/mL²
  - PSA velocity: 41.57 ng/mL/yr
  - Prior PSA: 125.1 ng/mL
  - Prostate volume: 46.38 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9718793 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease
  - Problem list / PMHx: Hypertension, Coronary artery disease
  - Current medication: valsartan, lisinopril, metoprolol, aspirin 80 mg
  - Allergies: NKA
  - Additional notes: PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.

Vitals: weight 61 kg, height 167 cm, BMI 21.9, BP 125/89 mmHg, HR 77 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2022).

Chief complaint: Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer.

History: A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time.

Physical examination: DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses.

Patient info: civil engineer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Tennis 2x/week; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.46
  uncertainty  +/- 0.15 epistemic (95% band 0.17-0.75); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.72: PI-RADS 5, PSA 160.0, PSAD 2.635, age 63, DRE Abnormal -> DEFER (clear). He wrote: "Start treating the patent. It does not make sense to not treat this man initially."
  2. distance 0.78: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  3. distance 1.33: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"

PRECEDENT: DEFER (weighted vote 0.23 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link the PI-RADS score and PSA density to the risk of clinically significant prostate cancer in biopsy-naïve men. The guideline suggests that a PSA density cut-off of 0.15 ng/mL/cc may guide the decision to perform a biopsy.

"linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is based solely on the structured panel, which ignores the clinical context that the patient has a prior positive biopsy and a PI-RADS 5 finding. The cohort criterion indicates that in this exact situation, the next step is staging and treatment, not further tissue sampling.

WHAT WE STILL NEED
The guideline requires information on the prior biopsy result and the PI-RADS score to apply the risk-adapted matrix. The panel shows a prior biopsy was positive and a PI-RADS score of 5, which are critical variables for this decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly suggests we need to establish the details of the prior biopsy result and the specific findings from the MRI report to apply the EAU risk-adapted matrix.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What are the specific findings regarding lesion size, zone, and extraprostatic extension?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What was the GRADE (Gleason or ISUP) of the prior positive biopsy?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What was the GRADE (Gleason or ISUP) of the prior positive biopsy?
  Q2. What are the specific findings regarding lesion size, zone, and extraprostatic extension from the radiology report?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate
Reporting Facility: Spaarne Gasthuis, Haarlem
Examination Date: 28 January 2025
Clinical Indication: Re-assessment prompted by a markedly elevated PSA measurement of 190.0 and a history of a positive biopsy.
FINDINGS: Glandular volume registers at 46.38 mL. T2-weighted sequences highlight a sharply demarcated, profoundly hypointense area spanning roughly 28 x 22 x 20 mm within the left peripheral zone at the base and mid-gland. Diffusion-weighted imaging shows intense signal restriction paired with correspondingly low apparent diffusion coefficient readings. Dynamic contrast studies capture early, focal enhancement confined to this region. Neither extraprostatic extension nor seminal vesicle invasion is evident. Pelvic lymph nodes appear normal.
IMPRESSION: PI-RADS 5 lesion located in the left peripheral zone. Prostate volume 46.38 mL; PSA density 4.097 ng/mL/mL. csPCa predicted probability 0.9718793.

psa_trend
{"date": "Dec 2023", "val": 15.3}
{"date": "Apr 2024", "val": 3.3}
{"date": "Sep 2024", "val": 19.1}
{"date": "Feb 2025", "val": 190.0}

previous_notes
{"date": "12 Aug 2023", "author": "Dr. E. Mulder (GP)", "text": "Early 2023 screening yielded a PSA of 38 ng/mL, which climbed to 86.0 ng/mL by December 2023. This steep trajectory in a 66-year-old individual necessitated an urgent urology referral to initiate mpMRI planning and comprehensive evaluation."}

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not required to answer the specific questions posed by the moderator.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion located in the left peripheral zone.
PSA density 4.097 ng/mL/mL.

AGAINST sampling this patient now
Prior biopsy: Positive.

WHERE THIS LEANS
The MRI confirms a high-risk lesion (PI-RADS 5) in the peripheral zone, which aligns with the cohort criterion suggesting staging/treatment over further biopsy.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (clear). Last value 190.00 ng/mL over 4 points spanning 14 months; velocity +141.74 ng/mL per year; doubling time about 3 months.
PROJECTION at 6 months: 720.4 ng/mL, conformal 95% band 206.7-2511.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.41
  uncertainty  +/- 0.13 epistemic (95% band 0.16-0.66), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.46  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.41  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.23  (k=3 precedents)
  EXPERT-COHORT      DEFER  (rule psa_ge_20)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—address the moderator's questions. The radiology report details lesion size (28 x 22 x 20 mm), zone (left peripheral zone), and confirms no extraprostatic extension. The previous notes mention the prior biopsy was positive, but the specific GRADE (Q1) is not recorded in the retrieved documents.

ALIGNMENT WITH THE PANEL
The Panel Protocol concluded NO BIOPSY based on the cohort criterion (PSA $\ge 20$ ng/mL) firing. The retrieved evidence supports the high-risk nature of the lesion (PI-RADS 5, size 28x22x20 mm) which aligns with the cohort criterion's implication that staging/treatment is preferred over further biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What was the GRADE (Gleason or ISUP) of the prior positive biopsy? This information is missing from the retrieved documents.
Q2. What are the specific findings regarding lesion size, zone, and extraprostatic extension from the radiology report? This was answered by the radiology_report, which noted a lesion of 28 x 22 x 20 mm in the left peripheral zone with no extraprostatic extension.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 finding and the size of the lesion (28 x 22 x 20 mm) carry the most weight because they confirm a high-risk finding, which supports the Panel Protocol's decision to defer biopsy based on the cohort criterion. The missing prior biopsy grade is a critical variable for a complete risk assessment but does not overturn the panel's conclusion based on the retrieved data.

MY SUGGESTION TO THE CHAIR
I suggest deferring the biopsy, as the high-risk MRI findings, specifically the PI-RADS 5 lesion size, align with the cohort criterion that prioritizes staging and treatment over further tissue sampling in this context.

VERDICT: ready | SUGGEST: defer | MISSING: GRADE (Gleason or ISUP)

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the cohort criterion fired based on the PSA value of 190.0 ng/mL, which aligns with the finding that the patient already has a tissue diagnosis. The high-risk MRI finding, specifically the PI-RADS 5 lesion size of 28 x 22 x 20 mm, supports the cohort criterion that prioritizes staging and treatment over further tissue sampling. The evidence converged on deferral, as the high-risk imaging features outweigh the need for additional biopsy in this context.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
